Thursday, 22 October 2020


Sharp Corp develops air purifying device to fight COVID-19

30 September 2020 | News

Sharp has been demonstrating the effectiveness of Plasmacluster technology by working with third-party research organizations

A device, developed by Japan headquartered Sharp Corporation, equipped with Plasmacluster technology, which exposed an airborne novel coronavirus (SARS-CoV-2) to Plasmacluster ions for approximately 30 seconds, has effectively reduced the infectious titer of the virus by more than 90% for the first time in the world.

This achievement was accomplished in collaboration with Professor Jiro Yasuda of the National Research Center for the Control and Prevention of Infectious Diseases/Institute of Tropical Medicine, Nagasaki University, Professor Asuka Nanbo (a board member of the Japanese Society for Virology) of the same institution, Professor Hironori Yoshiyama of the Department of Microbiology, Shimane University, Faculty of Medicine (also, a board member of the Japanese Society for Virology), and Nagasaki University, an internationally respected authority on infectious diseases research.

In 2004, Sharp demonstrated the effectiveness of Plasmacluster technology against feline (cat) coronavirus, a member of the Corona viridae family. In the following year of 2005, Sharp also demonstrated its effectiveness against the original SARS coronavirus (SARS- CoV), which caused the outbreak of 2002-2003 and is also genetically similar to the novel coronavirus (SARS-CoV-2). Now, Sharp has demonstrated its effectiveness against SARS-CoV-2 in airborne droplets. 

Since 2000, Sharp has been demonstrating the effectiveness of Plasmacluster technology by working in collaboration with independent third-party research organizations around the world. So far, numerous independent research organizations have proven its clinical efficacy in suppressing the activity of harmful substances including new pandemic influenza viruses, drug-resistant bacteria, and mite allergens, as well as in reducing bronchial inflammation levels in children with asthma.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account